Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has submitted to NSE and BSE copies of the newspaper advertisements it published regarding its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. The advertisements were published in Financial Express (English) and Financial Express (Gujarati) editions. This filing is being made under Regulation 47 of SEBI's Listing Obligations and Disclosure Requirements, 2015. The underlying results were approved by the Board of Directors at a meeting held on February 12, 2026, and signed by Managing Director Mahendra G. Patel. No specific financial numbers from Lincoln Pharmaceuticals are reproduced in this particular filing — it is a procedural compliance submission confirming that the Q3 results have been disseminated publicly via newspaper as required by SEBI rules.
This is a routine regulatory compliance filing and does not contain new financial information. The actual Q3 and 9M FY26 results were already approved by the Board on February 12, 2026, and this submission simply confirms the company has met SEBI's newspaper publication requirement under Regulation 47. Shareholders looking for the detailed numbers should refer to the earlier results filing or the company's investor page.